LENZ
LENZ Therapeutics, Inc.
Key Financials
Revenue
$19.1M
↑ Infinity%
Operating Income
$-91138000
↓ 55.5%
Net Income
$-82127000
↓ 65.0%
Total Liabilities
$21.5M
↑ 92.0%
EPS (Diluted)
$-2.85
↓ 21.8%
Cash & Equivalents
$25.2M
↑ 24.9%
Total Assets
$305.9M
↑ 42.1%
Shareholders' Equity
$284.3M
↑ 39.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 8-K | 7/2/2026 | View on SEC |
| SCHEDULE 13G | 6/26/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LENZ |
| Company Name | LENZ Therapeutics, Inc. |
| CIK | 1815776 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-925-7000 |